A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

NCT01974440 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

403

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Bendamustine
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: PCI-32765 (Ibrutinib)
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]